SCHEMBL14770548

SCHEMBL14770548

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4ccccc4)nc3)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.44
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770568 0.89 MEN1 (0.47) MEN1HTTKMT2AKDM4EALDH1A1
SCHEMBL12065311 0.89 FFAR1 (0.47) FFAR1MEN1HTTKMT2ALOXL2
SCHEMBL14770601 0.81 PTGES (0.51) MEN1HTTKMT2AKDM4EALDH1A1
SCHEMBL14770605 0.81 MEN1 (0.46) FFAR1MEN1HTTKMT2AKDM4E
SCHEMBL14770595 0.80 MAOA (0.44) MEN1HTTKMT2AALDH1A1NPC1
SCHEMBL14770619 0.80 KMT2A (0.43) MEN1HTTKMT2AKDM4EALDH1A1
SCHEMBL14770573 0.80 MEN1 (0.46) FFAR1MEN1HTTKMT2ANPC1
SCHEMBL14770571 0.79 KMT2A (0.46) FFAR1MEN1HTTKMT2AMAPT
SCHEMBL14770587 0.79 MEN1 (0.46) FFAR1MEN1HTTKMT2ANPC1
SCHEMBL12065253 0.79 MEN1 (0.43) FFAR1MEN1HTTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A FFAR1 1112/4885MEN1 2676/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.